VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older

Trial Profile

VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs AT 342 (Primary)
  • Indications Crigler-Najjar syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VALENS
  • Sponsors Audentes Therapeutics
  • Most Recent Events

    • 10 Aug 2017 According to an Audentes Therapeutics media release, the company plans to report preliminary clinical data from this study by the end of 2017.
    • 10 Aug 2017 According to an Audentes Therapeutics media release, the company plans to initiate this trial (enroll and dose the first patient) in the third quarter of 2017.
    • 18 Jul 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top